Profound Medical

PROF

Market cap $205M

The consensus price target hints at an 82.4% upside potential for Profound Medical (PROF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

– CAPTAIN is the first randomized controlled trial ever comparing a new technology to the standard of care of robotic radical prostatectomy to successfully recruit to target – – CAPTAIN is the first randomized controlled trial ever comparing a new technology to the standard of care of robotic radical prostatectomy to successfully recruit to target –

New BPH module and clinical data reinforce the TULSA Procedure™'s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption New BPH module and clinical data reinforce the TULSA Procedure™'s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption

Profound Medical (PROF) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PROF's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

After losing some value lately, a hammer chart pattern has been formed for Profound Medical (PROF), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Profound Medical (PROF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The consensus price target hints at a 97.6% upside potential for Profound Medical (PROF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Renowned urologist Dr. Mark Hong sets new global benchmark for urologist-led, MRI-guided prostate treatment, leading a growing movement toward incision-free prostate therapy Renowned urologist Dr. Mark Hong sets new global benchmark for urologist-led, MRI-guided prostate treatment, leading a growing movement toward incision-free prostate therapy

Profound Medical Corp. ( PRN:CA ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Stephen Kilmer - Investor Relations Rashed Dewan Mathieu Burtnyk - President Thomas Tamberrino - Chief Commercial Officer Arun Menawat - Chairman of the Board & CEO Conference Call Participants Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division John McAulay - Stifel, Nicolaus & Company, Incorporated, Research Division Michael Freeman - Raymond James Ltd., Research Division Presentation Operator Good day, and thank you for standing by.

Profound Medical (PROF) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.38 per share a year ago.